You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ultraviolet Light Devices for Vitamin D

    SBC: APOLLO LIGHT SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Vitamin D deficiency is now recognized as a significant health problem for middle-aged and older adults. Vitamin D deficiency exacerbates osteoporosis and causes the bone disease, osteomalacia. Vitamin D deficiency increases risk of skeletal fractures. It is well known that the ultraviolet B portion of the solar spectrum is responsible for the cutaneous product ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  2. TITLE OMITTED

    SBC: APOLLO LIGHT SYSTEMS, INC.            Topic: N/A

    N/A

    STTR Phase I 1998 Department of Health and Human Services
  3. Tribosupplementation of Injured Joints

    SBC: TRIBOLOGICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Injury is a well established risk factor in the pathogenesis of osteoarthritis (OA) as supported by several large longitudinal population studies. Patients with meniscal and ACL injuries in particular are at risk for early OA. Chondroprotection of the joint surface is mediated by lubricin which forms an ordered nanofilm and provides anti-adhesion via steric rep ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Anti Inflammatory Membranes for Implantable Biosensors

    SBC: APPLIED TISSUE AND MATERIALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The prolonged inflammatory response to an implant is one of the primary causes for the failure to integrate implanted devices into tissue. The source of inflammation common to almost all implants is the foreign body response. Based on evidence in the literature and from our research team, the inflammatory response is mediated by the reactive oxygen species gene ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  5. Convective Flow Tissue Assembly of Vascular Grafts

    SBC: APPLIED TISSUE AND MATERIALS, INC.            Topic: N/A

    Coronary heart disease accounts for the largest fraction of heart disease (the leading cause of death in the United States, affecting 12 million Americans) and has an annual cost to society that exceeds 110 billion dollars. There is a great clinical need for small diameter vascular artery grafts, as patients requiring multiple or repeat bypass procedures frequently lack adequate autogenous vessels ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Amino acid derived urea based chemicals as sEH inhibitor

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent findings indicate that increasing levels of epoxides of arachidonic acid (EETs) appear to be new and excellent means to treat both hypertension and vascular inflammation. We demonstrated that in vivo inhibition of soluble epoxide hydrolase resulted in higher levels of EETs and in reduction of blood pressure and inflammation in animal models. Because the ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Novel epoxide hydrolase inhibitor for stroke prevention

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): A major cause of morbidity and mortality is the progression of organ damage associated with cardiovascular diseases. For instance, the incidence of stroke and costs associated with stroke damage continues to have a devastating impact on public health despite numerous treatments aimed at cardiovascular risk factors. Recent findings indicate that increasing lev ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. USING AL TO ENHANCE VR ANXIETY DISORDER TREATMENT

    SBC: ARGUS VR INTERNATIONAL            Topic: N/A

    DESCRIPTION (provided by applicant) This project will develop an artificial intelligence to provide the core functionality for virtual reality and computer based treatments for anxiety disorders. The use of artificial intelligence offers a number of advantages over existing treatments: (1) artificial intelligence provides personalized treatment - using multiple real time physiologic and subjective ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis

    SBC: Aridis Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is an autosomal recessive disorder, which leads to the abnormal composition and physical properties of airway secretions in CF patients. Additionally, the lungs of CF patients are particularly susceptible to chronic bacterial infections with >80% of CF patients becoming chronically infected by 18 years of life with mucoid forms of Pseudomon ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Quantitation Pulmonary Delivery of Therapeutic Protein

    SBC: Arizeke Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Arizeke Pharmaceuticals, Inc. is focused on the pulmonary delivery of protein therapeutics (including antibodies) to treat pulmonary disease. Arizeke's technology provides a unique ability to deliver large therapeutic proteins into the lung parenchyma and interstitium and into the lymphatic drainage system. Examples of indications that can be targeted by this t ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government